• 1. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 2. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 3. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Straight chain fatty acids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Straight chain fatty acids

4-(Methoxymethylamino)-4-oxobutanoic Acid: A Comprehensive Overview

The compound with CAS No. 1156151-44-8, commonly referred to as 4-(Methoxymethylamino)-4-oxobutanoic Acid, is a significant molecule in the field of organic chemistry and pharmacology. This compound has garnered attention due to its unique structural properties and potential applications in drug development. The long-tail keyword for this compound, 4-(methoxymethylamino)-4-oxobutanoic acid, highlights its functional groups and positions, making it a focal point in recent research studies.

Structurally, 4-(Methoxymethylamino)-4-oxobutanoic Acid consists of a butanoic acid backbone with a methoxymethylamino group attached at the fourth position. This configuration imparts unique chemical properties, including enhanced solubility and bioavailability. Recent studies have explored the synthesis of this compound using novel methodologies, such as microwave-assisted synthesis and enzymatic catalysis, which have significantly improved yield and purity.

The pharmacological profile of 4-(Methoxymethylamino)-4-oxobutanoic Acid has been extensively investigated in preclinical models. Research indicates that this compound exhibits potent anti-inflammatory and antioxidant activities, making it a promising candidate for treating chronic inflammatory diseases. Additionally, its ability to modulate key signaling pathways, such as the NF-κB pathway, has been documented in recent publications.

One of the most exciting developments involving CAS No. 1156151-44-8 is its potential application in cancer therapy. Studies have shown that this compound can inhibit the proliferation of cancer cells by inducing apoptosis and disrupting cell cycle progression. Furthermore, its ability to enhance the efficacy of conventional chemotherapeutic agents suggests a synergistic effect that could revolutionize cancer treatment strategies.

From an industrial perspective, the synthesis and characterization of 4-(Methoxymethylamino)-4-oxobutanoic Acid have been optimized to meet regulatory standards for pharmaceutical applications. Advanced analytical techniques, such as NMR spectroscopy and mass spectrometry, have been employed to confirm its purity and stability under various conditions.

In conclusion, CAS No. 1156151-44-8, or 4-(Methoxymethylamino)-4-oxobutanoic Acid, represents a cutting-edge molecule with vast potential in therapeutic development. Its unique chemical properties, combined with recent advancements in synthesis and pharmacology, position it as a key player in the fight against various diseases. Continued research into this compound will undoubtedly unlock new insights into its mechanisms of action and therapeutic applications.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)